DeepMed Research

Reistone Biopharma Company Limited

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Phase 3

Active, not recruiting

Conditions: Alopecia Areata

Interventions: Drug: SHR0302
Drug: Placebo

First Posted Date: 2022-07-22

Last Posted Date: 2023-09-05

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 330

Registration Number: NCT05470413

Locations: 🇨🇳
Zhujiang Hospital of Southern Medical University, Guanzhou, Guangdong, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China

and more 28 locations

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: SHR0302

First Posted Date: 2022-01-06

Last Posted Date: 2023-09-05

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 368

Registration Number: NCT05181137

Locations: 🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
🇺🇦
Clinical Hospital "Feofaniia", Kyiv, Ukraine
🇺🇦
Communal Noncommercial Enterprise of Lviv Regional Council "Lviv Regional Clinical Hospital", Lviv, Ukraine

and more 110 locations

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

Phase 2

Active, not recruiting

Conditions: Primary Membranous Nephropathy

Interventions: Drug: SHR1459 Low Dose
Drug: SHR1459 High Dose
Drug: Placebo

First Posted Date: 2021-11-29

Last Posted Date: 2023-09-05

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 61

Registration Number: NCT05136456

Locations: 🇨🇳
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳
The First Affiliated Hospital of Baotou Medical College, Baotou, Nei Monggol, China
🇨🇳
Zhongshan Hospital Xiamen University, Xiamen, Fujian, China

and more 16 locations

Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

First Posted Date: 2021-05-06

Last Posted Date: 2023-06-01

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 336

Registration Number: NCT04875169

Locations: 🇨🇦
The Centre for Dermatology, Richmond Hill, Ontario, Canada
🇨🇦
Clinique D, Laval, Quebec, Canada
🇨🇳
Zhejiang province People's Hospital, Hangzhou, China

and more 49 locations

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

Phase 2

Terminated

Conditions: Vitiligo

Interventions: Drug: Low Dose SHR0302 Ointment BID
Drug: High Dose SHR0302 Ointment BID

First Posted Date: 2021-03-01

Last Posted Date: 2022-07-13

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 75

Registration Number: NCT04774809

Locations: 🇨🇳
Wuhan No.1 Hospital, Wuhan, Hubei, China
🇨🇳
Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
Ningbo No.2 Hospital, Ningbo, Zhejiang, China

and more 13 locations

Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Phase 2

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: SHR0302 Ointment
Drug: Vehicle

First Posted Date: 2021-01-22

Last Posted Date: 2023-09-05

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 645

Registration Number: NCT04717310

Locations: 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
🇨🇳
Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China
🇨🇳
Zhejiang province People's Hospital, Hangzhou, China

and more 28 locations

An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

Phase 2

Completed

Conditions: Neuromyelitis Optica Spectrum Disorders

Interventions: Drug: Drug - SHR1459

First Posted Date: 2020-12-17

Last Posted Date: 2023-03-23

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 10

Registration Number: NCT04670770

Locations: 🇨🇳
Xiangya Hospital Of Central South University, Changsha, China
🇨🇳
Lanzhou University Second Hospital, Lanzhou, China
🇨🇳
People's Hospital of Rizhao, Rizhao, China

and more 5 locations

A Phase II Study in Patients With Alopecia Areata

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: SHR0302

First Posted Date: 2020-04-15

Last Posted Date: 2021-07-16

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 94

Registration Number: NCT04346316

Locations: 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

and more 26 locations

A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

First Posted Date: 2019-11-14

Last Posted Date: 2023-05-09

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 105

Registration Number: NCT04162899

Locations: 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳
Beijing Tsinghua Changgeng Hospital, Beijing, China
🇨🇳
Peking University People's Hospital, Xicheng, Beijing, China

and more 20 locations

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: SHR0302
Drug: Placebos

First Posted Date: 2018-09-19

Last Posted Date: 2023-03-15

Lead Sponsor: Reistone Biopharma Company Limited

Target Recruit Count: 112

Registration Number: NCT03677648

Locations: 🇵🇱
Gabinet Lekarski Bartosz Korczowski, Rzeszów, Poland
🇵🇱
SALVE Zakład Opieki Zdrowotnej Sp. zo.o., Łódź, Poland
🇺🇦
I.I.Mechnykov Dnipropetrovsk, Dnipro, Ukraine

and more 76 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy